Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F9 | P00740 | 11/20 | 0.39 |
| ▸ | F11 | P03951 | 5/20 | 0.39 |
| ▸ | F7 | P08709 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 3/20 | 0.33 |
| ▸ | KMO | O15229 | 2/20 | 0.33 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9607651 | 0.85 | KMO (0.37) | F9F11F7LMNAGAA | |
| SCHEMBL1232278 | 0.80 | F9 (0.50) | F9F11F7LMNAGAA | |
| SCHEMBL1232822 | 0.79 | F9 (0.62) | F9F11F7LMNAGAA | |
| SCHEMBL9607649 | 0.76 | F9 (0.66) | F9F11F7GAAMAPT | |
| SCHEMBL10116777 | 0.75 | LMNA (0.40) | LMNA | |
| SCHEMBL10116291 | 0.71 | LMNA (0.37) | LMNA | |
| SCHEMBL10116442 | 0.71 | LMNA (0.37) | LMNAKMO | |
| SCHEMBL9607765 | 0.69 | F9 (0.44) | F9F11F7LMNACYP2C9 | |
| SCHEMBL10105805 | 0.68 | KMO (0.37) | LMNAKMO | |
| SCHEMBL10116429 | 0.68 | LMNA (0.34) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136016-A1 | 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS | F9, F8, F12 | F9 1/4885F11 5/4885F7 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.